09-09-2019
Press release: Smartfish initiates global collaboration with B. Braun, securing forceful launch of its medical nutrition product Remune
OSLO, NORWAY AND LUND, SWEDEN, SEPTEMBER 9, 2019.
Smartfish AS has initiated a strategic collaboration with the global healthcare company B. Braun to secure a forceful global launch of its medical nutrition product Remune. B. Braun will launch Remune in close to 20 countries during 2019 and 2020, followed by several other markets in Europe, Asia and South America. The collaboration also opens up for potential future launches by B. Braun of other innovative products based on Smartfish’s technology.
Based on its proprietary emulsion technology, Smartfish provides unique nutrition products with high levels of Omega 3 fatty acids, whey protein and other nutrients. Since the technology prevents oxidation of the Omega 3 fatty acids DHA and EPA, the products have an excellent taste – an important factor since poor compliance is a major concern within the medical nutrition field. Smartfish’s medical nutrition products are used to improve the nutritional status of malnourished or undernourished patients and has shown statistically significant effects in clinical trials in cancer and COPD patients. Recently published data from a double-blinded, placebo-controlled pilot study indicate that Remune can improve overall survival in undernourished patients with non-small-cell lung cancer [1].
“Smartfish is a research-focused life science company and finding the right distributors to efficiently reach the global market is a crucial part of our business model. The collaboration with B. Braun is the result of a thorough process and marks the beginning of a global launch of our products,” comments Smartfish’s CEO Geir Harstad.
B. Braun will be responsible for the launch of Remune in close to 20 countries during 2019 and 2020, followed by several other markets in Europe, Asia and South America. As a leading global healthcare company, B. Braun markets innovative medical products and services in 64 countries around the world, with a pronounced strategy to further grow its presence in the medical nutrition area.
“B. Braun has a strong focus on serving cancer patients with well-documented products throughout the patient journey, and has built up a strong cancer portfolio. Remune has shown unique characteristics and we are confident that this will make a real difference for cancer patients. Hence, we are delighted by this opportunity to offer Remune as part of our global product portfolio. We also see room for expanding our collaboration in the future, with the aim to provide patients in need with further innovative products based on Smartfish’s technology”, comments Angelika Müller, Vice President Global Marketing and Sales Critical Care at B. Braun.
For more information, please contact:
Jens Nordahl, VP Sales & Marketing, tel +47 996 299 99
About Smartfish AS
Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice-based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway and Lund, Sweden. Smartfish’s main shareholders are Investinor (Norway) and Industrifonden (Sweden).
Learn more on www.smartfishnutrition.com
About B. Braun
With over 60.000 employees in 64 countries, B. Braun is one of the world's leading manufacturers of medical devices and pharmaceutical products and services. Through constructive dialogue, B. Braun develops high quality product systems and services that are both evolving and progressive - and in turn improve people's health around the world.
